Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 11/26/2009 - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 11/12/2009 - (DGNews)
    Anti-TNF Treatment Does Not Increase Cancer Risk in Patients With RA - (DGNews)
    TopAbstracts in Rheumatoid Arthritis 10/29/2009 - (DGNews)
    Tocilizumab Plus Methotrexate Provides Sustained Benefits in Patients With RA: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
      Comorbidity in Patients with Rheumatoid Arthritis: What are the Real Concerns?
      Advances in Basic Science
      Quantitatively-Driven Management of Rheumatoid Arthritis
      Cancer, Liver, Infections, Cardiovascular Disease, and other Biologic Agents
      Rheumatoid Arthritis: Clinical Aspects, Outcomes, and Measures

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Mesenteric Rheumatoid Nodules Masquerading as an Intra-Abdominal Malignancy: A Case Report and Review of the Literature
        Co-Existence of Acute Myeloid Leukemia with Multilineage Dysplasia and Epstein-Barr Virus-Associated T-Cell Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis
        Patient with Hepatitis B and Rheumatoid Arthritis
        Complete Heart Block and Severe Aortic Stenosis in a Patient with Rheumatoid Arthtritis: A Case Report
        Limited Wegener's Granulomatosis Presenting as Lung Nodules in a Patient with Rheumatoid Arthritis: A Case Report

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Concomitant Leflunomide Improves Response to Methotrexate in Patients with Persistent Rheumatoid Arthritis

        A DGReview of :"Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial"
        Annals of Internal Medicine

        11/08/2002
        By David Loshak


        Addition of leflunomide to methotrexate provides statistically significant clinical benefit to patients with persistent rheumatoid arthritis who do not respond to methotrexate alone.

        This combination is generally well tolerated, report specialists at 20 leading centres in the United States and Canada. The combination can be used safely with appropriate liver enzyme and haematological monitoring, they say.

        Their study assessed the efficacy and safety of leflunomide, a disease-modifying anti-rheumatic drug, versus placebo when added to ongoing, stable-dose methotrexate, an antimetabolite agent, in a 24-week, randomised, double-blind trial.

        Patients had had persistently active rheumatoid arthritis as defined by standard American College of Rheumatology criteria that did not respond to at least six months of methotrexate treatment.

        The primary efficacy variable was the rate of achievement of a 20 percent improvement in American College of Rheumatology criteria (ACR20) at the end of the study. The Health Assessment Questionnaire Disability Index was determined at each visit and the Medical Outcomes Study 36-Item Short Form was completed as an end point analysis.

        At 24 weeks, 46.2 percent of patients given leflunomide met ACR20 criteria compared with 19.5 percent of those given placebo (p<0.001). Clinical improvement was shown by statistically significant mean changes in individual components of the ACR20 response criteria.

        The two groups had similar discontinuation rates (23.1 versus 24.8 percent.) and incidences of adverse events (89.2 versus 89.5 percent), which were chiefly mild or moderate.
        Annals of Internal Medicine 2002;137(9):726-733. "Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send